Effect of tempol on myocardial vascular remodeling in female spontaneously hypertensive rats

Histology and Histopathology

Volumn 27, Issue 8, 2012, Pages 1047-1054

  Bonacasa, Barbara ^a   Hernandez I ^a   Fenoy, F J ^a   Quesada, T ^a   Lopez B ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Estrogen; Hypertension; Oxidative stress; Tempol; Vascular remodeling

Indexed keywords

AMINE OXIDE; ANTIOXIDANT; ESTRADIOL; TEMPOL;

ANIMAL; ARTICLE; BLOOD PRESSURE; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; FEMALE; HEART VENTRICLE REMODELING; HYPERTENSION; OVARIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPIN LABELING; SPONTANEOUSLY HYPERTENSIVE RAT; TUNICA MEDIA;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CORONARY VESSELS; CYCLIC N-OXIDES; DRUG ANTAGONISM; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HYPERTENSION; OVARIECTOMY; RATS; RATS, INBRED SHR; SPIN LABELS; TUNICA MEDIA; VENTRICULAR REMODELING;

EID: 84864960189     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bonacasa B., Sanchez M.L., Rodriguez F., Lopez B., Quesada T., Fenoy F.J. and Hernandez I. (2008). 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. Maturitas 61, 310-316.
2. Castro M.M., Rizzi E., Rodrigues G.J., Ceron C.S., Bendhack L.M., Gerlach R.F. and Tanus-Santos J.E. (2009). Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic. Biol. Med. 46, 1298-1307.
3. Cave A.C., Brewer A.C., Narayanapanicker A., Ray R., Grieve D.J., Walker S. and Shah A.M. (2006). NADPH oxidases in cardiovascular health and disease. Antioxid. Redox Signal 8, 691-728.
4. Czernichow S., Bertrais S., Blacher J., Galan P., Briancon S., Favier A., Safar M. and Hercberg S. (2005). Effect of supplementation with antioxidants upon long-term risk of hypertension in the SU. VI. MAX study: Association with plasma antioxidant levels. J. Hypertens. 23, 2013-2018.
5. Dikalova A., Clempus R., Lassegue B., Cheng G., McCoy J., Dikalov S., San M.A., Lyle A., Weber D.S., Weiss D., Taylor W.R., Schmidt H.H., Owens G.K., Lambeth J.D. and Griendling K.K. (2005). Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112, 2668-2676.
6. Dimmeler S. and Zeiher A.M. (2007). A "reductionist" view of cardiomyopathy. Cell 130, 401-402.
7. Droge W. (2002). Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95.
8. Farhat M.Y., Lavigne M.C. and Ramwell P.W. (1996). The vascular protective effects of estrogen. FASEB J. 10, 615-624.
9. Fortepiani L.A. and Reckelhoff J.F. (2005). Role of oxidative stress in the sex differences in blood pressure in spontaneously hypertensive rats. J. Hypertens. 23, 801-805.
10. Fortepiani L.A., Zhang H., Racusen L., Roberts L.J. and Reckelhoff J.F. (2003). Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension 41, 640-645.
11. Garcia P.M., Gimenez J., Bonacasa B., Carbonell L.F., Salom M.G., Quesada T. and Hernandez I. (2005). 17beta-estradiol exerts a beneficial effect on coronary vascular remodeling in the early stages of hypertension in spontaneously hypertensive rats. Menopause 12, 453-459.
12. Garcia M.P., Gimenez J., Serna M., Salom M.G., Bonacasa B., Carbonell L.F., Quesada T. and Hernandez I. (2006). Effect of estrogen and angiotensin-converting enzyme inhibitor on vascular remodeling in ovariectomized spontaneously hypertensive rats. Menopause 13, 397-403.
13. Gerhard M. and Ganz P. (1995). How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation 92, 5-8.
14. Grassi G., Seravalle G., Scopelliti F., Dell'Oro R., Fattori L., Quarti-Trevano F., Brambilla G., Schiffrin E.L. and Mancia G. (2010). Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 18, 92-98.
15. Halliwell B. (2000). The antioxidant paradox. Lancet 355, 1179-1180.
16. Heagerty A.M., Aalkjaer C., Bund S.J., Korsgaard N. and Mulvany M.J. (1993). Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 21, 391-397.
17. Hernandez I., Delgado J.L., Diaz J., Quesada T., Teruel M.J., Llanos M.C. and Carbonell L.F. (2000). 17beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J. Physiol. Regul. Integr. Comp. Physiol. 279, R1599-R1605.
18. Hilenski L.L., Clempus R.E., Quinn M.T., Lambeth J.D. and Griendling K.K. (2004). Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 24, 677-683.
19. Intengan H.D. and Schiffrin E.L. (2001). Vascular remodeling in hypertension: Roles of apoptosis, inflammation, and fibrosis. Hypertension 38, 581-587.
20. Isles C.G., Hole D.J., Hawthorne V.M. and Lever A.F. (1992). Relation between coronary risk and coronary mortality in women of the renfrew and paisley survey: Comparison with men. Lancet 339, 702-706.
21. Keaney J.F. Jr, Shwaery G.T., Xu A., Nicolosi R.J., Loscalzo J., Foxall T.L. and Vita J.A. (1994). 17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 89, 2251-2259.
22. Kim M.K., Sasaki S., Sasazuki S., Okubo S., Hayashi M. and Tsugane S. (2002). Lack of long-Term effect of vitamin C supplementation on blood pressure. Hypertension 40, 797-803.
23. Kumar S., Lata K., Mukhopadhyay S. and Mukherjee T.K. (2010). Role of estrogen receptors in pro-oxidative and anti-oxidative actions of estrogens: a perspective. Biochim. Biophys. Acta 1800, 1127-1135.
24. Landmesser U. and Harrison D.G. (2001). Oxidative stress and vascular damage in hypertension. Coron. Artery Dis. 12, 455-461.
25. Lassegue B. and Clempus R.E. (2003). Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R277-R297.
26. Lassegue B. and Griendling K.K. (2010). NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 30, 653-661.
27. Lopez-Ruiz A., Sartori-Valinotti J., Yanes L.L., Iliescu R. and Reckelhoff J.F. (2008). Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am. J. Physiol. Heart Circ. Physiol. 295, H466-H474.
28. Madamanchi N.R., Vendrov A. and Runge M.S. (2005). Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 29-38.
29. McQueen M.J., Lonn E., Gerstein H.C., Bosch J. and Yusuf S. (2005). The HOPE (Heart Outcomes Prevention Evaluation) study and its consequences. Scand. J. Clin. Lab. Invest. Suppl. 240, 143-156.
30. Nishiyama A., Yoshizumi M., Hitomi H., Kagami S., Kondo S., Miyatake A., Fukunaga M., Tamaki T., Kiyomoto H., Kohno M., Shokoji T., Kimura S. and Abe Y. (2004). The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in dahl salt-sensitive rats. J. Am. Soc. Nephrol. 15, 306-315.
31. Palumbo G., Avanzini F., Alli C., Roncaglioni M.C., Ronchi E., Cristofari M., Capra A., Rossi S., Nosotti L., Costantini C. and Cavalera C. (2000). Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension Study. Am. J. Hypertens. 13, 564-567.
32. Paravicini T.M. and Touyz R.M. (2008). NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31 Suppl 2, S170-S180.
33. Pires P.W., Deutsch C., McClain J.L., Rogers C.T. and Dorrance A.M. (2010). Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats. Microvasc. Res. 80, 445-452.
34. Rigsby C.S., Pollock D.M. and Dorrance A.M. (2007). Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc. Res. 73, 198-205.
35. Sakurabayashi-Kitade S., Aoka Y., Nagashima H., Kasanuki H., Hagiwara N. and Kawana M. (2009). Aldosterone blockade by spironolactone improves the hypertensive vascular Hhypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 206, 54-60.
36. Sartori-Valinotti J.C., Iliescu R., Fortepiani L.A., Yanes L.L. and Reckelhoff J.F. (2007). Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin. Exp. Pharmacol. Physiol. 34, 938-945.
37. Schnackenberg C.G., Welch W.J. and Wilcox C.S. (1998). Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32, 59-64.
38. Schneider M.P., Delles C., Schmidt B.M., Oehmer S., Schwarz T.K., Schmieder R.E. and John S (2005). Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am. J. Hypertens. 18, 1111-1117.
39. Shao D., Oka S.I., Brady C.D., Haendeler J., Eaton P. and Sadoshima J. (2012). Redox modification of cell signaling in the cardiovascular system. J. Mol. Cell. Cardiol. 52, 550-558.
40. Soule B.P., Hyodo F., Matsumoto K., Simone N.L., Cook J.A., Krishna M.C. and Mitchell J.B. (2007). The chemistry and biology of nitroxide compounds. Free Radic. Biol. Med. 42, 1632-1650.
41. Sun D., Huang A., Koller A. and Kaley G. (1995). Flow-dependent dilation and myogenic constriction interact to establish the resistance of skeletal muscle arterioles. Microcirculation 2, 289-295.
42. Thorndike E.A. and Turner A.S. (1998). In search of an animal model for postmenopausal diseases. Front. Biosci. 3, c17-c26.
43. Vokurkova M., Xu S. and Touyz R.M. (2007). Reactive oxygen species, cell growth, cell cycle progression and vascular remodeling in hypertension. Future Cardiol. 3, 53-63.
44. Ward N.C., Wu J.H., Clarke M.W., Puddey I.B., Burke V., Croft K.D. and Hodgson J.M. (2007). The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J. Hypertens. 25, 227-234.
45. Wenger N.K. (2008). Drugs for cardiovascular disease prevention in women: implications of the AHA guidelines-2007 update. Drugs 68, 339-358.
46. Wilcox C.S. and Pearlman A. (2008). Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol. Rev. 60, 418-469.
47. Xing D., Nozell S., Chen Y.F., Hage F. and Oparil S. (2009). Estrogen and mechanisms of vascular protection. Arterioscler. Thromb. Vasc. Biol. 29, 289-295.
48. Zalba G., Beaumont J., San J.G., Fortuno A., Fortuno M.A. and Diez J. (2000). Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J. Physiol. Biochem. 56, 57-64.
49. Zalba G., Gonzalez A., Beaumont J., San J.G., Moreno U., Lopez B., Ravassa S., Muniz P., Fortuno A., Fortuno M.A. and Diez J. (2001). Vascular oxidative stress and endothelial dysfunction. Nefrologia 21 (Suppl 1), 61-66.